ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed
a new class of GLP-1 therapies entirely through artificial
intelligence, designed to enhance efficacy, safety, therapy
longevity, and patient satisfaction in diabetes treatment. These
AI-designed therapeutics aim to improve upon current GLP-1
therapies, which are widely used for managing type 2 diabetes and
obesity. Created using the Company's proprietary LENSai™ platform,
an AI-driven system that analyzes evolutionary patterns in
biological data, these novel AI-generated sequences have been
optimized to maximize therapeutic performance while improving the
patient experience. Enhancements are aimed at increased
patentability, extended stability and resistance to degradation,
improved administration routes for greater compliance, reduced
dosing requirements, and more efficient manufacturing methods. The
Company’s GLP-1-like alternatives are currently being evaluated for
potential transdermal delivery as non-invasive alternatives to
injections. These novel constructs represent the Company's first
fully AI-generated assets, complementing their growing portfolio of
AI-assisted and laboratory-developed therapies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20250122287383/en/
IPA Antibody Therapeutics Pipeline
(Graphic: Business Wire)
Advancing GLP-1 Therapies
Current GLP-1 drugs for diabetes and obesity management often
require frequent injections due to their short half-life. In just
two weeks, IPA's LENSai generated, developed and optimized novel
genetic sequences for GLP-1-like constructs that may offer
potential advantages over existing treatments. IPA is now
investigating whether genetic constructs based on these optimized
sequences could support more efficient dosing regimens and enhance
patient experience. This rapid sequence generation process
showcases LENSai's transformative potential in drug discovery,
leveraging its unique ability to identify specific patterns
embedded in biological material. This approach could revolutionize
therapeutic innovation across multiple disease areas, enabling
faster and more precise in silico drug development.
From AI Discovery to Preclinical Optimization
IPA’s LENSai™ platform identified key molecular features by
analyzing evolutionary patterns across species. Using HYFT®
technology, the potential therapeutics were refined to improve
binding strength, increase resistance to enzymatic breakdown, and
optimize their function. Instead of chemical modifications to
increase therapeutic stability, a standard industry method, IPA
applied rational genetic engineering to enhance peptide longevity
and performance in early-stage studies.
Additionally, IPA has optimized its GLP-1 alternatives for
compatibility with nucleic acid-based expression systems in
collaboration with Aldevron, LLC (a Danaher company). While IPA has
strategically aligned its therapies with an established nucleic
acid delivery technology, its AI-driven approach has tailored the
genetic sequences to leverage specific delivery enhancements,
including increased gene expression and reduced immune response
risks. By incorporating optimized genetic elements, IPA aims to
explore long-term, stable therapeutic production within the body as
part of its ongoing pre-clinical investigations.
Exploring a Novel Drug Delivery Approach
Given the unique and miniature nature of the therapeutic
molecules as well as their selected gene therapy delivery vehicle,
IPA is further evaluating the feasibility of delivering these
GLP-1-like therapies via a transdermal patch rather than injection.
This concept could allow for a steady, controlled release of the
peptide, potentially improving absorption and patient convenience.
The AI-driven drug optimizations are designed to ensure
compatibility with this delivery method, providing a foundation for
further investigation into non-invasive metabolic treatments.
A Paradigm Shift in Biologic Innovation
IPA's proprietary HYFT patterns, the core of our LENSai
software, are driving a revolution in therapeutic drug discovery.
These unique patterns, exclusive to IPA, enable:
- Entirely in silico drug discovery, development, and
optimization
- Rapid and precise code execution
- Reduced energy consumption
"LENSai's continued breakthroughs underscore the unparalleled
power of our HYFT patterns," said Dr. Jennifer Bath, CEO of
ImmunoPrecise Antibodies. "These patterns, which only IPA
possesses, are the key to unlocking unprecedented speed and
precision in biologics research. LENSai is not just accelerating
development—it's redefining the very process of therapeutic
innovation."
This approach positions LENSai at the forefront of
next-generation biologics, providing end-to-end in silico drug
development capabilities with optimized safety and efficacy
screening from the earliest stages of development, whether used by
IPA or licensed to partners in the industry.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that
leverages multi-omics modeling and complex artificial intelligence
through a series of proprietary and patented technologies. The
Company owns an integrated end-to-end suite of capabilities to
support the development of therapeutic antibodies and are known for
solving very complex industry challenges. IPA has several
subsidiaries in North America and Europe including entities such as
Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies
(Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V.
(collectively, the “IPA Family”).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of applicable United States and Canadian securities
laws. Forward-looking statements often include words such as
“expects,” “intends,” “anticipates,” “believes,” or variations
thereof, or state that certain actions, events, or results “may,”
“will,” “could,” or “might” occur. These statements relate to,
among other things, the anticipated benefits and impact of the
AI-driven peptide discovery pipeline, the potential for
computationally designed GLP-1 analogs to improve therapeutic
efficacy, and the Company’s ability to develop and commercialize
transdermal GLP-1 candidates.
Although the Company believes it has a reasonable basis for
these forward-looking statements, they are based on current
expectations, assumptions, and projections about future events that
involve risks and uncertainties. Actual results may differ
materially from those expressed or implied due to factors largely
beyond the Company’s control, including risks related to scientific
and technological developments, regulatory approvals, industry
competition, and broader market conditions.
Forward-looking statements involve known and unknown risks,
uncertainties, and other factors that may cause actual results,
performance, or achievements to differ materially from those
expressed or implied herein. Additional information on risks and
uncertainties can be found in the Company’s Annual Report on Form
20-F, as amended, for the year ended April 30, 2024 (available on
the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile
at www.sec.gov/edgar). Should any of these risks materialize,
actual results could vary significantly.
Readers are cautioned not to place undue reliance on
forward-looking statements, which reflect the Company’s
expectations only as of the date of this release. The Company
assumes no obligation to update or revise these statements, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250122287383/en/
Investor Relations Contact
investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
過去 株価チャート
から 12 2024 まで 1 2025
ImmunoPrecise Antibodies (NASDAQ:IPA)
過去 株価チャート
から 1 2024 まで 1 2025
